INTRODUCTION
Multiple guidelines exist for the treatment of hypertension. The goal of hypertension treatment is usually to reduce blood pressure to the recommended range. A drug of a different class can be added to antihypertensive for patients who fail to achieve control in blood pressure [1] .
Angiotensin II receptor blockers (ARBs) are currently the most popular class of drugs used in the treatment of hypertension. ARBs are considered good agents in terms of tolerability, the convenience of a once-daily dose, and efficiency in lowering blood pressure. Telmisartan is an ARB that has high affinity to the AT1 receptor subtype and exhibits a long half-life [2] [3] [4] . Fixed-dose combinations (FDCs) containing telmisartan have been developed with the diuretic hydrochlorothiazide (HCTZ) or calcium channel blocker amlodipine as two active pharmaceutical ingredients [5] [6] [7] [8] .
A telmisartan-amlodipine combination treatment resulted in clinically relevant blood pressure reduction, and was well tolerated with good compliance [8] . Furthermore, compared with monotherapy in patients with previously uncontrolled blood pressure, the addition of HCTZ to telmisartan has been associated with effective blood pressure reduction, as well as with improved hypertension goal-attainment rates [9] .
Amlodipine is an orally active, long-lasting dihydropyridine calcium channel blocker (CCB) used to treat hypertension; the drug works by dilating blood vessels and is available in doses of 5 and 10 mg. Amlodipine is also used to treat certain types of chest pain [10] .
HCTZ is a diuretic medication used to reduce the reabsorption of electrolytes from renal tubules, and is often prescribed to treat high blood pressure. It works by increasing urinary output and reducing the amount of fluid in the blood [7] [8] [9] .
Combination therapy for hypertension can be effective by lowering blood pressure and reducing cardiovascular disease, such as stroke [11, 12] .
FDCs of antihypertensive agents with different modes of action provide many advantages in treatment while maintaining lower doses of each component drug. Other benefits of FDCs include improvement of compliance, as patients are only required to take one dosage form, and a lower cost of therapy [12] [13] [14] .
To develop new dosage forms of FDCs, it is necessary to show that the FDC administered is therapeutically equivalent to the combined single-drug doses.
The comparison of therapeutic equivalence can be conducted by evaluating the pharmacokinetic parameters to investigate whether the rate and extent of absorption of individual FDC components are similar to those of the coadministered reference products.
The purpose of this clinical trial was to develop FDCs containing the three drugs, and evaluate the pharmacokinetic profiles after the single-dose and tolerability. The results of this study were used to demonstrate the bioequivalence between test and reference products. After fasting for 10 h, the subjects took the test or reference items with 150 mL of water. Standard meals were provided at 4 th and 10 th h after administration.
METHODS

Materials
Subjects were forbidden from eating grape fruits 7 days before the first period through the last sampling in the fourth period because a number of calcium channel blockers can interact with the CYP3A4 metabolic enzyme [18] .
Blood sampling
For pharmacokinetic analysis, blood were collected before administration and at 0. 25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 , and 144 h. Seven milliliters of blood were collected into EDTA tubes. Only 5 mL was collected at 72 h and 3 mL at 96 and 144 h. Plasma was prepared by centrifugation of the blood samples at 3,000 rpm for 10 min at 4 °C. Samples were stored at −70 °C in polypropylene tubes until analysis.
Pharmacokinetic analysis
Analysis of each drug was performed at Biosuntek Laboratories Co. (Seongnam, Korea), which is certified by the MFDS as employing GLP. The methods used have been validated as standard operating procedures and followed MFDS guidelines on bioanalytical method validation [19] .
The concentration of telmisartan, amlodipine, and HCTZ in plasma were analyzed by validated LC-MS/MS methods; the pharmacokinetic parameters of each drug were assessed by WinNonlin software (Pharsight, Sunnyvale, CA, USA), including AUC last (h•ng/mL), C max (ng/mL), AUC inf (h•ng/mL), T max (h), and t 1/2 (h).
Samples were stored at −70 °C until assay and mixed with an internal standard after thawing. Each component was extracted from the plasma using protein precipitation. The liquid chromatographic method used for separation was isocratic.
In the telmisartan assay, the mobile phase consisted of a mixture of ACN (Acetonitrile, A) with 5 mM ammonium formate(B) (A:B=7:3) with a flow rate of 0.25 mL/min and column temperature of 40 °C. Detection was conducted with a positive electrospray ionization multiple reaction monitoring mode set to transmit at m/z 515.3 → 276.2 and 441.0 → 263.2 for telmisartan and the internal standard, respectively [20, 21] .
In the amlodipine assay, the mobile phase consisted of a mixture of ACN(A) with 0.1 % formic acid in water(B) (1:1) with a flow rate of 0.3 mL/min and a column temperature of 40 °C. Detection was conducted with a positive electrospray ionization multiple reaction monitoring mode set to transmit at m/z 409.4 → 238.1 and 413.4 → 238.1 for amlodipine and the internal standard, respectively [22, 23] .
In the HCTZ assay, the mobile phase consisted of a mixture of water and methanol (15:85), with a flow rate of 0.3 mL/min and a column temperature of 40 °C. Detection was conducted with a negative electrospray ionization multiple reaction monitoring mode set to transmit at m/z 296.0 → 269.0 and 338.2 → 78.1 for HCTZ and the internal standard, respectively [21, 24] .
As the primary parameters for establishing bioequivalence, AUC last and C max were evaluated for all components, and AUC inf , T max , t 1/2 , CL/F, and Vd/F as secondary parameters.
Tolerability assessment
Tolerability was assessed from a medical review of adverse events (AEs), clinical laboratory evaluation, vital sign measurements, physical examinations, and electrocardiograms. The subjects who had an experience of taking investigational products at least once were targets of the evaluation.
Statistical analysis
All participants who had an experience of taking the investigational products were used in statistical analysis of tolerability and only those who finished the study were used in the analysis of pharmacokinetic parameters. The parameters were calculated as the geometric mean.
Establishing bioequivalence according to MFDS regulations was conducted as an estimate of the 90 % CIs of primary parameters (AUC last and C max ) for all drugs.
RESULTS
Demographic profile of study subjects Six subjects were excluded when they withdrew consent, one was excluded due to an AE (epigastric pain, diarrhea), and one due to concomitant medication. Thus, 32 subjects completed the study (Figure 1 ).
Pharmacokinetics
The pharmacokinetic parameters of telmisartan, amlodipine, and HCTZ were derived by noncompartmental methods from plasma concentration time curves. The mean plasma concentrations of each drug were similar between the test and reference items; pharmacokinetic parameters are summarized in Table 2. For telmisartan, the 90 % CIs of the GMRs of AUC last (h•ng/mL), C max (ng/mL) were 0.9414 -1.0496, 1.0246 -1.2792 and CV (Coefficient of variation) of C max for telmisartan was 41.96 %. The MFDS has been defined as a highly variable drug (HVD) that has a 30 % or greater intrasubject variability of the C max . The bioequivalent acceptance range of 90% CIs of C max for telmisartan was 0.7363 -1.3580.
The 90 % CIs of the GMRs for all components were summarized in Table 3 satisfying the MFDS criteria for evaluation of bioequivalence. In previous pharmacokinetic studies, the variation of intra-subjects for telmisartan, amlodipine besylate and HCTZ were similar to this study [25, 26] . Figure 2 shows the mean plasma concentrationtime profiles for telmisartan, amlodipine and HCTZ and the test and reference items did not show noticeable difference in T max or t 1/2 .
Tolerability
All subjects did not show any serious or unexpected AEs and were considered to be well tolerated. Overall, 40 subjects received FDCs or reference products and 8 subjects experienced 11 AEs. Six AEs were recorded in four subjects who were administered FDCs, and five AEs in four subjects who were administered reference products.
Two AEs were moderate (upper abdominal pain, diarrhea), and the other cases were mild and considered related to the investigational items.
DISCUSSION
In this clinical study, pharmacokinetics profiles and tolerability of newly developed FDCs were investigated in Korean male subjects and compared with co-administration of each reference item.
The pharmacokinetic parameters of telmisartan, amlodipine, and HCTZ were similar profiles between the test and reference product groups in a replicate crossover study design. However the T max of telmisartan and HCTZ of test was slightly faster than co-administration of reference items, but this difference was not expected to have a significantly influence on overall absorption. Also, since the C max and AUC are major evaluation criteria of bioequivalence by the MFDS, we did not consider parameter of T max further.
The 90 % CIs of the GMRs for AUC last and C max of all drugs were satisfactory with regard to bioequivalence range 0.8 to 1.25 or 0.7363 -1.3580. This finding from the bioavailability suggested that a replicate crossover study was well designed for newly developed FDCs especially with telmisartan.
In the tolerability, noticeable interaction between telmisartan, amlodipine and HCTZ has not been reported in previous research. Despite coadministration of the highest dose on the markets, serious and unexpected AEs were not different between the FDC groups and the reference product co-administration groups.
The findings from pharmacokinetic profiles and tolerability indicate that these FDCs can be expected to exhibit similar safety and efficacy as commercially marketed products. The newly developed FDCs can replace the coadministration of reference products expected improvement of compliance for patients.
To clear the result of safety and efficacy clinically, other studies will be needed in large scale hypertensive patients.
CONCLUSION
A developed FDC tablet containing telmisartan/amlodipine/HCTZ combination (80/10/25 mg) is bioequivalent to a co-administered commercially available telmisartan/ amlodipine combination and HCTZ tablets at equivalent concentrations. In this clinical study there were no serious or unexpected AEs and noticeable difference in the FDC groups and the reference product co-administration groups.
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